Amblyopia Market Information: By Type (Strabismus Amblyopia, Refractive Amblyopia), Diagnosis (Visual Acuity Tests, Photo Screening), Treatment (Eye Patches, Atropine Drops, Glasses, Video Game), End-User (Ophthalmic Clinics) – Global Forecast Till 2023
Amblyopia is an eye disorder which leads to decreased vision in one or both the eyes due to suppressed input from the brain. The most common cause of amblyopia is a refractive error in one or both eyes, or it might even occur due to muscle imbalance. The other cause of amblyopia is if the infant is born with a cataract, which causes cloudy images. There are four types of amblyopia, namely, Strabismus Amblyopia, Refractive Amblyopia, Deprivation Amblyopia, and Reverse Amblyopia. The global prevalence rate of Amblyopia is 2 to 3% of the infant population. Amblyopia market is driven by growing incidence of ophthalmological disorders such as cataracts, macular degeneration, glaucoma, and refractive errors. According to reports published by the United Kingdom Statistics Authority, in 2015, around 15,900 people were registered as visually impaired. Moreover, according to the Journal of Ophthalmology, as of 2014 there were around 28 million visually impaired people in the European region. With the increasing prevalence, there is increasing in the advancement of treatment and hence influencing the growth of the Amblyopia market size.
Amblyopia, commonly known as lazy eye, is a vision impairment disorder, in which one or both the eyes have reduced or no vision. Amblyopia can begin during infancy or early childhood. Amblyopia requires detection and diagnosis early in childhood, which otherwise can lead to blindness during later life. On the basis of type, amblyopia can be divided into, Strabismic amblyopia, Refractive amblyopia, Deprivation amblyopia, and Reverse Amblyopia.
Global amblyopia market is expected to grow at a CAGR of 3.80% during the forecast period 2017-2023.
Key Players
- Amblyoptica (Holding) Pty Ltd,
- Amblyotech, Inc,
- Good-Lite Co,
- Vivid Vision, Inc.,
- Cooper Vision,
- Johnson & Johnson,
- Novartis AG.,
- Carl Zeiss AG,
- HOYA Corporation,
- Krafty Eye Patches¸
- Fresnel Prism and Lens Co.,
- Hilco Vision,
- McKesson Corporation
Segmentation
The global amblyopia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis the type, it is segmented into strabismus amblyopia, refractive amblyopia, deprivation amblyopia, reverse amblyopia, and other.
On the basis of the diagnosis, it is segmented into visual acuity tests, photo screening, Bruckner test and others.
On the basis of the treatment, it is segmented into eye patches, atropine drops, glasses, video game and others.
On the basis of the end-user, it is segmented into hospitals & pharmacies, ophthalmic clinics, and others.
Regional analysis
The global amblyopia market, on the basis of region, is divided into the Americas, Europe, Asia Pacific and the Middle East & Africa. The Americas accounted for the largest amblyopia market share of 37.9% in 2016 for global amblyopia market. This large share is majorly attributed due to the increasing prevalence of ophthalmological disorders, the presence of major manufacturers, increasing technological advancement and high healthcare expenditure. Europe accounts for the second largest market share, whereas Asia Pacific is expected to grow at the fastest rate with 4.35% CAGR for the forecast period. With lots of opportunity and continuously growing economies, the presence of huge patient population, rapid development in technology and presence of a huge opportunity for the development the region is expected to be the fastest growing region. The Middle East & Africa is growing at a slow pace, and the low income accounted for the least market share in 2016 but is expected to grow in the coming future.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/amblyopia-market-4353
Macular Degeneration Treatment Market is also known as age-related macular degeneration (AMD) is a neurodegenerative ocular disorder that destroy the part of the eye called the macula which provides sharp, central vision needed for seeing objects clearly.
When macula degenerates, it causes loss of central vision.
It occurs when the capillaries around the fovea widen (become dilated) and leak, results in fluid build-up which impairing reflection of light and causing progressive vision loss.
The first symptom usually is a night blindness as disease progress person develops tunnel vision and eventually leads to loss of central vision.According to the statistics published in the press release by Neurotech, an estimated population of Macular telangiectasia type 2 is nearly around 1 per 22,000 worldwide.
High demand of novel treatment and huge investment on research and development are drivers for market growth.macular degeneration treatment market is expected to grow at a steady CAGR in the forecast period of 2019-2026.
The report also recognizes and analyses the rising trends along with major drivers, challenges and opportunities in the market.
